Johnson & Johnson (JNJ)vsSensus Healthcare Inc (SRTS)
JNJ
Johnson & Johnson
$255.57
+0.90%
HEALTHCARE · Cap: $613.99B
SRTS
Sensus Healthcare Inc
$2.77
0.00%
HEALTHCARE · Cap: $49.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 559271% more annual revenue ($97.93B vs $17.51M). JNJ leads profitability with a 21.5% profit margin vs -88.4%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SRTS
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.1%
Fair Value
$141.74
Current Price
$255.57
$113.83 premium
Margin of Safety
-70.6%
Fair Value
$2.79
Current Price
$2.77
$0.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Earnings expanding 433.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Revenue declined 68.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : SRTS
The strongest argument for SRTS centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : SRTS
The primary concerns for SRTS are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SRTS is a turnaround play — different risk/reward profiles.
SRTS carries more volatility with a beta of 1.14 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 33/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Sensus Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?